916591-01-0 Usage
Uses
Used in Pharmaceutical Industry:
4,7-Methano-1H-indazole-3-carboxamide, 1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-, (4S,7R)is used as a cannabinoid receptor modulator for treating non-immediate type allergic diseases. Its unique structure allows it to interact with cannabinoid receptors in the body, which play a role in regulating immune responses and inflammation. This makes it a promising candidate for the development of new therapeutic agents to address various allergic conditions.
Note: Since the provided materials only mention the use of Tedalinab, a cannabinoid receptor modulator, for treating non-immediate type allergic diseases, the description and uses of 4,7-Methano-1H-indazole-3-carboxamide, 1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-, (4S,7R)are inferred based on the given information. Additional research and data would be required to provide a more comprehensive and accurate description of the compound's properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 916591-01-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,5,9 and 1 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 916591-01:
(8*9)+(7*1)+(6*6)+(5*5)+(4*9)+(3*1)+(2*0)+(1*1)=180
180 % 10 = 0
So 916591-01-0 is a valid CAS Registry Number.
916591-01-0Relevant academic research and scientific papers
NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION
-
Page/Page column 61, (2008/12/08)
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION
-
Page/Page column 171, (2010/11/25)
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CBl) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
